Jun 22, 2023 / 08:30PM GMT
Operator
Good afternoon, and welcome to the Sarepta Therapeutics ELEVIDYS FDA accelerated approval call. (Operator Instructions) As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, President and CEO of Sarepta Therapeutics. Please go ahead.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you, Victor. And thank you all for joining us for this call to discuss the approval and launch of the first and only approved gene therapy for Duchenne muscular dystrophy. Mary, next slide. I will be making some forward-looking statements. Please refer to our public filings for the various risks and uncertainties that exist with statements and predictions about the future. Next slide. As you know, earlier today, the FDA approved RP SRP-9001, delandistrogene moxeparvovec-rokl for the treatment of Duchenne patients. The division has initially approved the therapy for Duchenne patients aged 4 through 5 years with our ongoing Phase III trial EMBARK, acting as the confirmatory study for the approval. And
Sarepta Therapeutics Inc ELEVIDYS FDA Accelerated Approval Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers